CompletedPhase 4

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

United States250 participantsStarted 2011-09-09

Plain-language summary

This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin. The purpose of this study is to compare infection-related hospital length of stay, along with a number of participant-reported outcomes, between participants with complicated skin and soft tissue infection treated with daptomycin and vancomycin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Further defined as infections either involving deeper soft tissue or requiring significant surgical intervention or infections in which the participant has a significant underlying disease state that complicates the response to treatment
✓. Are suspected or documented to be caused by MRSA
✓. At least 3 of the following clinical signs and symptoms associated with the cSSSI:

What they're measuring

Infection-Related Hospital Length of Stay

Timeframe: Baseline (Day 0) through the End of Hospital Stay (up to Day 14)

Trial details

NCT IDNCT01419184

SponsorCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-09-01

Results submitted2015-04-23

View on ClinicalTrials.gov More Staphylococcal Skin Infections trials